Press "esc" to clear
Go to Advanced Search
Showing results 1120 of 239
photo_4.jpg

Article ID: 698417

Ebola Virus - Subject Matter Experts

Georgetown University Medical Center

WASHINGTON — Georgetown University professors offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include infectious disease control and treatment, vaccine development, clinical trials, global health security, and international health regulations. To schedule an interview, please contact Karen Teber at km463@georgetown.

Released:
1-Aug-2018 2:05 PM EDT
CroweLab2018SU1_edited-1.jpg

Article ID: 698263

Vanderbilt Team Finds Potent Antibodies Against Three Ebola Viruses

Vanderbilt University Medical Center

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.

Released:
30-Jul-2018 3:15 PM EDT
BatesPNASEbolavirusparticlesredonalargercellNIH.jpg

Article ID: 696615

Proteins Found in Semen Increase the Spread of Ebola Virus Infection

Perelman School of Medicine at the University of Pennsylvania

Protein fragments, called amyloid fibrils, in human semen significantly increase Ebola virus infection and protect the virus against harsh environmental conditions such as heat and dehydration. Follow-up studies from the 2014 epidemic found that men can harbor the virus in their semen for at least 2.5 years, with the potential to transmit the virus sexually during that time. Targeting amyloids in semen may prevent a sexually transmitted spread of the Ebola virus.

Released:
25-Jun-2018 3:50 PM EDT
hemo-virus-vaccine-large.jpg

Article ID: 694538

Vaccine-Induced Antibodies Against One Hemorrhagic Fever Virus Found to Disarm Related Virus for Which There Is No Vaccine

Harvard Medical School

Research conducted in vitro shows two human antibodies made in response to vaccination against one hemorrhagic fever virus can disarm a related virus, for which there is currently no vaccine. The proof-of-principle finding identifies a common molecular chink in the two viruses’ armor that renders both vulnerable to the same antibodies. The results set the stage for a single vaccine and other antibody-based treatments that work against multiple viral “cousins” despite key differences in their genetic makeup. Such therapies can alleviate challenges posed by current lack of vaccines and prevent outbreaks of viral hemorrhagic fevers.

Released:
14-May-2018 2:30 PM EDT
Ebola.jpg

Article ID: 694529

Mapping the Body’s Battle with Ebola and Zika

Los Alamos National Laboratory

The viruses that cause Ebola and Zika, daunting diseases that inspire concern at every outbreak, share a strong similarity in how they first infiltrate a host’s cells.

Released:
14-May-2018 12:05 PM EDT
bsquare-300x300.jpg

Article ID: 691734

Researchers Identify Chemical Compound That Inhibits Ebola Virus Replication

Georgia State University

An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.

Released:
26-Mar-2018 3:05 PM EDT
GGH_6168.JPG
  • Embargo expired:
    22-Feb-2018 9:30 AM EST

Article ID: 689866

Promising Treatment for Ebola Virus to be Tested at Texas Biomed

Texas Biomedical Research Institute

During the West African Ebola outbreak that began in 2013, an experimental biopharmaceutical drug called ZMappTM was a glimmer of hope in the midst of a health crisis. Now, scientists at Texas Biomedical Research Institute in San Antonio have been awarded a $2 million dollar contract by the makers of ZMapp, Mapp Biopharmaceutical, Inc., to further test this promising new therapeutic.

Released:
20-Feb-2018 4:15 PM EST

Showing results 1120 of 239

Chat now!